Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Given Consensus Recommendation of “Moderate Buy” by Analysts

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) has earned a consensus recommendation of “Moderate Buy” from the eleven research firms that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, nine have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $37.1111.

A number of equities analysts have recently commented on TEVA shares. Bank of America raised their target price on shares of Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the stock a “buy” rating in a research report on Tuesday, December 9th. Piper Sandler increased their price objective on Teva Pharmaceutical Industries from $30.00 to $40.00 and gave the stock an “overweight” rating in a research note on Monday, December 22nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research report on Wednesday, January 21st. Truist Financial upped their target price on Teva Pharmaceutical Industries from $36.00 to $38.00 and gave the stock a “buy” rating in a report on Thursday, January 29th. Finally, Barclays raised their price target on Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the company an “overweight” rating in a research note on Friday, January 30th.

Teva Pharmaceutical Industries Stock Performance

TEVA stock opened at $33.96 on Tuesday. Teva Pharmaceutical Industries has a twelve month low of $12.47 and a twelve month high of $37.35. The firm has a market cap of $39.05 billion, a price-to-earnings ratio of 28.30, a PEG ratio of 1.94 and a beta of 0.70. The business’s fifty day simple moving average is $32.20 and its two-hundred day simple moving average is $24.67. The company has a quick ratio of 0.80, a current ratio of 1.04 and a debt-to-equity ratio of 1.89.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings results on Wednesday, January 28th. The company reported $0.96 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.31. The firm had revenue of $4.71 billion for the quarter, compared to analysts’ expectations of $4.36 billion. Teva Pharmaceutical Industries had a net margin of 8.16% and a return on equity of 46.28%. The business’s revenue for the quarter was up 11.4% on a year-over-year basis. During the same period in the prior year, the business posted $0.71 earnings per share. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. Analysts predict that Teva Pharmaceutical Industries will post 2.5 earnings per share for the current year.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other news, VP Richard Daniell sold 115,468 shares of the company’s stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $28.68, for a total value of $3,311,622.24. Following the completion of the sale, the vice president owned 48,384 shares of the company’s stock, valued at approximately $1,387,653.12. This represents a 70.47% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Amir Weiss sold 12,300 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $30.20, for a total transaction of $371,460.00. Following the transaction, the chief accounting officer directly owned 5,650 shares in the company, valued at approximately $170,630. The trade was a 68.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 422,060 shares of company stock worth $12,254,965. Company insiders own 0.55% of the company’s stock.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Several institutional investors have recently bought and sold shares of TEVA. Phoenix Financial Ltd. grew its holdings in Teva Pharmaceutical Industries by 9.4% in the third quarter. Phoenix Financial Ltd. now owns 41,295,244 shares of the company’s stock valued at $834,164,000 after purchasing an additional 3,533,800 shares during the period. National Pension Service raised its stake in shares of Teva Pharmaceutical Industries by 24.2% during the 3rd quarter. National Pension Service now owns 2,073,293 shares of the company’s stock worth $41,881,000 after buying an additional 404,526 shares during the period. Oak Harvest Investment Services purchased a new position in shares of Teva Pharmaceutical Industries during the 3rd quarter valued at approximately $1,010,000. Harel Insurance Investments & Financial Services Ltd. lifted its position in shares of Teva Pharmaceutical Industries by 12.9% during the 3rd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 37,696,690 shares of the company’s stock valued at $761,455,000 after buying an additional 4,306,363 shares in the last quarter. Finally, Teacher Retirement System of Texas grew its stake in Teva Pharmaceutical Industries by 11.2% in the 3rd quarter. Teacher Retirement System of Texas now owns 697,574 shares of the company’s stock valued at $14,091,000 after acquiring an additional 69,994 shares during the period. 54.05% of the stock is currently owned by institutional investors and hedge funds.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.